Silicon Laboratories Inc.: Q2 FY2026 earnings call

What management said about Q2 FY2026, from the documents filed with the SEC on 11 August 2026: press release. The quarter’s numbers.

Key takeaways

Revenue rose 18% to $228 million: Revenue was $228.2 million against $192.8 million a year earlier, up 18%. The first-quarter release reported $214 million. Source
Non-GAAP EPS reached $0.71: Non-GAAP diluted earnings per share was $0.71, up 545% from the comparable period, compared with $0.53 in the first quarter. Source
Industrial and Commercial rose 23%: Industrial & Commercial revenue was $135 million, up 23% from a year earlier, after $128 million in the first quarter, which was up 33%. Source
Medical revenue set a record: Medical revenue was a record for the quarter and was up 78%. The release does not state which reported segment medical sits in this quarter. Source
Bookings accelerated as channel inventory fell: Management said bookings and new orders accelerated while inventory at distributors and end customers declined. No book-to-bill figure was given for this quarter. Source
Gross margin near 62%: GAAP gross margin was 61.6% and non-GAAP gross margin was 61.9%, against 59.5% and 59.7% in the first quarter. Gross profit was $140.7 million. Source
Operating cash flow negative for six months: For the six months, net cash used in operating activities was $9.6 million, against $53.0 million provided in the prior-year period. Inventory changes used $27.7 million. Source
Guidance suspended pending acquisition: Forward-looking guidance is suspended because of the announced pending acquisition of Silicon Labs by Texas Instruments. No revenue, margin or EPS range is given. Source

“Overall profitability improved meaningfully in the quarter, demonstrating the operating leverage inherent in our model.”
Matt Johnson, President and Chief Executive Officer

Results and growth drivers

Revenue rose 18% to $228 million: Revenue was $228.2 million against $192.8 million a year earlier, up 18%. The first-quarter release reported $214 million. Source
Non-GAAP EPS reached $0.71: Non-GAAP diluted earnings per share was $0.71, up 545% from the comparable period, compared with $0.53 in the first quarter. Source
GAAP loss per share narrowed: GAAP diluted loss per share was $(0.32), against $(0.67) a year earlier. GAAP operating loss was $10.7 million, against $22.9 million a year earlier. Source

Segments, end markets and demand

Industrial and Commercial rose 23%: Industrial & Commercial revenue was $135 million, up 23% from a year earlier, after $128 million in the first quarter, which was up 33%. Source
Home and Life rose 12%: Home & Life revenue was $93 million, up 12% from a year earlier, after $86 million in the first quarter. Source
Medical revenue set a record: Medical revenue was a record for the quarter and was up 78%. The release does not state which reported segment medical sits in this quarter. Source
Bookings accelerated as channel inventory fell: Management said bookings and new orders accelerated while inventory at distributors and end customers declined. No book-to-bill figure was given for this quarter. Source

“Gross margin was nearly 62%, reflecting the value customers place on our industry-leading solutions.”
Matt Johnson, President and Chief Executive Officer

Margins, costs and non-GAAP basis

Gross margin near 62%: GAAP gross margin was 61.6% and non-GAAP gross margin was 61.9%, against 59.5% and 59.7% in the first quarter. Gross profit was $140.7 million. Source
Operating expenses rose on SG&A: GAAP operating expenses were $151.3 million, up from $131.0 million. SG&A was $56.3 million against $43.2 million, and R&D was $95.0 million against $87.8 million. Source
Merger costs excluded from non-GAAP: Non-GAAP results exclude merger-related costs of $9.5 million pre-tax, intangible amortization of $2.3 million, and stock compensation of $25.2 million. Source

Cash flow and capital spending

Operating cash flow negative for six months: For the six months, net cash used in operating activities was $9.6 million, against $53.0 million provided in the prior-year period. Inventory changes used $27.7 million. Source
Capital spending rose on equipment purchases: Purchases of property and equipment were $22.2 million for six months, against $13.5 million, partly offset by $5.3 million of capital-related government incentives. Source
Cash fell and stock award taxes rose: Cash and equivalents were $362.2 million and short-term investments were $35.1 million at July 4, 2026. Payments of taxes withheld for vested stock awards were $27.5 million, against $13.8 million. Source

Balance sheet and share count

Inventories and receivables rose: Inventories were $123.3 million at July 4, 2026, up from $95.6 million at January 3, 2026. Accounts receivable, net, rose to $79.8 million from $64.5 million. Source
Shares outstanding rose: Shares issued and outstanding were 33,366 thousand at July 4, 2026, against 32,955 thousand at January 3, 2026. The release reports no share repurchases or dividends. Source

Guidance, acquisition and management comments

Guidance suspended pending acquisition: Forward-looking guidance is suspended because of the announced pending acquisition of Silicon Labs by Texas Instruments. No revenue, margin or EPS range is given. Source
Acquisition moved from proposed to pending: The first-quarter release described a proposed merger that continued to advance. The second-quarter release describes an announced pending acquisition, with no closing date given.
CEO credited team execution: CEO Matt Johnson credited the revenue result to the execution and dedication of the Silicon Labs team. Source

Figures management reported

Figure	Reported
Gross margin Source	GAAP 61.6%; non-GAAP 61.9%
End-market revenue: Industrial & Commercial Source	$135 million, up 23% year-over-year
End-market revenue: Home & Life Source	$93 million, up 12% year-over-year
End-market revenue: medical Source	record quarterly revenue, up 78% year-over-year
Book-to-bill	multi-year high (first-quarter release)

Earlier plans management reported on

Met: The first-quarter release expected an 18% non-GAAP tax rate for the rest of the year. This release says that rate was applied. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.

As filed with the SEC

Open the filing on EDGAR

Silicon Labs Reports Second Quarter 2026 Results

Wireless IoT leader delivers $228 million in revenue and strong earnings growth

AUSTIN, Texas - August 11, 2026 - Silicon Labs (NASDAQ: SLAB), the leading innovator in low-power wireless, reported financial results for the second quarter, which ended July 4, 2026.

“We delivered revenue of $228 million, continuing our strong sequential and year-over-year growth - a testament to the execution and dedication of the Silicon Labs team,” said Matt Johnson, President and Chief Executive Officer. “Overall profitability improved meaningfully in the quarter, demonstrating the operating leverage inherent in our model. Gross margin was nearly 62%, reflecting the value customers place on our industry-leading solutions.”

Second Quarter Financial Highlights

Revenue was $228 million, up 18% year-over-year
Industrial & Commercial revenue was $135 million, up 23% year-over-year
Home & Life revenue was $93 million, up 12% year-over-year
Bookings and new orders accelerated, while inventory at both our distributors and end customers declined
Medical achieved record revenue in the quarter, up 78% year-over-year
Total opportunity funnel and design wins both materially accelerated, reinforcing our durable growth trajectory
GAAP diluted loss per share was $(0.32), improving by 52% over the comparable period last year
Non-GAAP diluted earnings per share was $0.71, up 545% over the comparable period last year

Results on a GAAP basis:

GAAP gross margin was 61.6%
GAAP operating expenses were $151 million
GAAP operating loss was $11 million
GAAP diluted loss per share was $(0.32)

Results on a non-GAAP basis, excluding the impact of stock compensation, amortization of acquired intangible assets, merger-related costs, and certain other items as set forth in the below GAAP to Non-GAAP reconciliation tables were as follows:

Non-GAAP gross margin was 61.9%
Non-GAAP operating expenses were $114 million
Non-GAAP operating income was $27 million
Non-GAAP diluted earnings per share was $0.71

Due to the announced pending acquisition of Silicon Labs by Texas Instruments, Silicon Labs has suspended providing forward-looking guidance.

About Silicon Labs

Silicon Labs (NASDAQ: SLAB) is the leading innovator in low-power wireless connectivity, building embedded technology that connects devices and improves lives. Merging cutting-edge technology into the world's most highly integrated SoCs, Silicon Labs provides device makers the solutions, support, and ecosystems needed to create advanced edge connectivity applications. Headquartered in Austin, Texas, Silicon Labs has operations in over 16 countries and is the trusted partner for innovative solutions in the smart home, industrial IoT, and smart cities markets. Learn more at silabs.com.

Forward-Looking Statements

Forward-looking statements notice

This press release contains forward-looking statements regarding Silicon Labs’ current expectations, which are based on its current views and assumptions. The words “believe”, “estimate”, “expect”, “intend”, “anticipate”, “plan”, “project”, “will”, and similar phrases as they relate to Silicon Labs are intended to identify such forward-looking statements, although the absence of such words does not necessarily mean a statement is not forward looking. These forward-looking statements include, but are not limited to, Silicon Labs’ expectations regarding its near- and long-term strength and durable growth trajectory and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations that are expressed or implied herein. Among the factors that could cause actual results to differ materially from those in the forward-looking statements are the following: our ability to complete the merger with Texas Instruments within the time frame expected, or at all, as well as potential disruptions in our business and restrictions on our activities during the pendency of the merger; fluctuating changes in global trade policies, including the imposition of tariffs, duties, trade sanctions, or other barriers to international commerce; the impact of the current global memory chip shortage; the competitive and cyclical nature of the semiconductor industry; the challenging macroeconomic environment, including disruptions in the financial services industry; geographic concentration of manufacturers, assemblers, test service providers and customers in Asia that subjects Silicon Labs’ business and results of operations to risks of natural disasters, epidemics or pandemics, war and political unrest; risks that demand and the supply chain may be adversely affected by military conflict (including in the Middle East, and between Russia and Ukraine), terrorism, sanctions or other geopolitical events globally (including in the Middle East, and conflict between Taiwan and China); risks that Silicon Labs may not be able to maintain its historical growth; quarterly fluctuations in revenues and operating results; difficulties developing new products that achieve market acceptance; risks associated with international activities (including trade barriers, particularly with respect to China); intellectual property litigation risks; risks associated with acquisitions and divestitures; product liability risks; difficulties managing and/or obtaining sufficient supply from Silicon Labs’ distributors, manufacturers and subcontractors; dependence on a limited number of products; absence of long-term commitments from customers; inventory-related risks; difficulties managing international activities; risks that Silicon Labs may not be able to manage strains associated with its growth; credit risks associated with its accounts receivable; dependence on key personnel; stock price volatility; the impact of public health crises on the U.S. and global economy; debt-related risks; capital-raising risks; the timing and scope of share repurchases and/or dividends; average selling prices of products may decrease significantly and rapidly; information technology risks; cyber-attacks against Silicon Labs’ products and its networks; risks associated with any material weakness in our internal controls over financial reporting; risks relating to compliance with laws and regulations; and other factors that are detailed in the SEC filings of Silicon Laboratories Inc. Silicon Labs disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. References in this press release to Silicon Labs shall mean Silicon Laboratories Inc.

Note to editors: Silicon Laboratories, Silicon Labs, the “S” symbol, and the Silicon Labs logo are trademarks of Silicon Laboratories Inc. All other product names noted herein may be trademarks of their respective holders.

For more information: Silicon Labs Investor Relations, investor.relations@silabs.com

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)

	Three Months Ended				Six Months Ended
	July 4, 2026		July 5, 2025		July 4, 2026		July 5, 2025
Revenues	$228,189		$192,845		$441,689		$370,559
Cost of revenues	87,515		84,736		174,017		164,673
Gross profit	140,674		108,109		267,672		205,886
Operating expenses:
Research and development	95,016		87,821		183,610		176,040
Selling, general and administrative	56,324		43,155		111,810		84,793
Operating expenses	151,340		130,976		295,420		260,833
Operating loss	(10,666)		(22,867)		(27,748)		(54,947)
Other income (expense):
Interest income and other, net	2,489		3,833		6,115		7,626
Interest expense	(251)		(251)		(483)		(535)
Loss before income taxes	(8,428)		(19,285)		(22,116)		(47,856)
Provision for income taxes	2,164		2,532		4,373		4,431
Net loss	$(10,592)		$(21,817)		$(26,489)		$(52,287)
Loss per share:
Basic	$(0.32)		$(0.67)		$(0.80)		$(1.61)
Diluted	$(0.32)		$(0.67)		$(0.80)		$(1.61)
Weighted-average common shares outstanding:
Basic		33,206		32,682		33,084		32,570
Diluted		33,206		32,682		33,084		32,570

Non-GAAP Financial Measurements

In addition to the GAAP results provided throughout this document, Silicon Labs has provided non-GAAP financial measurements on a basis excluding non-cash and other charges and benefits. Details of these excluded items are presented in the tables below, which reconcile the GAAP results to non-GAAP financial measurements.

The non-GAAP financial measurements do not replace the presentation of Silicon Labs’ GAAP financial results. These measurements provide supplemental information to assist management and investors in analyzing Silicon Labs’ financial position and results of operations. Silicon Labs has chosen to provide this information to investors to enable them to perform meaningful comparisons of past, present and future operating results and as a means to emphasize the results of core on-going operations.

Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures

(In thousands, except per share data)

	Three Months Ended July 4, 2026
Non-GAAP Income Statement Items	GAAP Measure	GAAP Percent of Revenue	Stock Compensation Expense	Intangible Asset Amortization	Merger-Related Costs	Non-GAAP Measure	Non-GAAP Percent of Revenue
Revenues	$228,189
Gross profit	140,674	61.6%	$463	$ -	$ -	$141,137	61.9%
Research and development	95,016	41.6%	12,902	2,295	3,289	76,530	33.5%
Selling, general and administrative	56,324	24.7%	12,284	-	6,258	37,782	16.6%
Operating expenses	151,340	66.3%	25,186	2,295	9,547	114,312	50.1%
Operating income (loss)	(10,666)	(4.7%)	25,649	2,295	9,547	26,825	11.8%

	Three Months Ended July 4, 2026
Non-GAAP Earnings (Loss) Per Share	GAAP Measure		Stock Compensation Expense*	Intangible Asset Amortization*	Merger-Related Costs*		Income Tax Adjustments**		Non- GAAP Measure
Net income (loss)	$(10,592)		$25,649	$2,295	$9,547		$(3,067)		$23,832
			Shares Excluded Due to Net Loss
Diluted shares outstanding		33,206				504		33,710
Diluted earnings (loss) per share	$(0.32)								$0.71

*Represents pre-tax amounts

** Represents the application of an 18% non-GAAP tax rate

Condensed Consolidated Balance Sheets

(In thousands, except per share data)

(Unaudited)

	July 4, 2026	January 3, 2026
Assets
Current assets:
Cash and cash equivalents	$362,191	$364,222
Short-term investments	35,051	79,400
Accounts receivable, net	79,801	64,513
Inventories	123,340	95,566
Prepaid expenses and other current assets	70,840	70,316
Total current assets	671,223	674,017
Property and equipment, net	130,902	128,643
Goodwill	376,389	376,389
Other intangible assets, net	18,541	23,130
Other assets, net	56,001	67,138
Total assets	$1,253,056	$1,269,317
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$52,407	$50,717
Deferred revenue and returns liability	5,176	5,359
Other current liabilities	66,563	87,711
Total current liabilities	124,146	143,787
Other non-current liabilities	34,108	31,112
Total liabilities	158,254	174,899
Commitments and contingencies
Stockholders’ equity:
Preferred stock - $0.0001 par value; 10,000 shares authorized; no shares issued	-	-
Common stock - $0.0001 par value; 250,000 shares authorized; 33,366 and 32,955 shares issued and outstanding at July 4, 2026 and January 3, 2026, respectively	3	3
Additional paid-in capital	184,456	157,402
Retained earnings	910,325	936,814
Accumulated other comprehensive income	18	199
Total stockholders’ equity	1,094,802	1,094,418
Total liabilities and stockholders’ equity	$1,253,056	$1,269,317

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

	Six Months Ended
	July 4, 2026	July 5, 2025
Operating Activities
Net loss	$(26,489)	$(52,287)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation of property and equipment	12,171	12,701
Amortization of other intangible assets	4,589	8,780
Stock-based compensation expense	46,704	39,605
Deferred income taxes	1,663	1,504
Changes in operating assets and liabilities:
Accounts receivable	(15,289)	(2,017)
Inventories	(27,734)	24,631
Prepaid expenses and other assets	(803)	5,112
Accounts payable	2,051	12,812
Other current liabilities and income taxes	(7,925)	8,377
Deferred revenue and returns liability	(183)	783
Other non-current liabilities	1,667	(6,965)
Net cash provided by (used in) operating activities	(9,578)	53,036
Investing Activities
Purchases of marketable securities	-	(32,507)
Sales of marketable securities	-	14,986
Maturities of marketable securities	44,119	17,019
Purchases of property and equipment	(22,153)	(13,549)
Proceeds from capital-related government incentives	5,272	-
Net cash provided by (used in) investing activities	27,238	(14,051)
Financing Activities
Payment of taxes withheld for vested stock awards	(27,451)	(13,752)
Proceeds from the issuance of common stock	7,760	7,619
Net cash used in financing activities	(19,691)	(6,133)
Increase (decrease) in cash and cash equivalents	(2,031)	32,852
Cash and cash equivalents at beginning of period	364,222	281,607
Cash and cash equivalents at end of period	$362,191	$314,459